Last reviewed · How we verify
NCT02951299
The Protective Effect of Pentoxifylline on Acute Kidney Injury
Phase 2, PHASE3 trial testing Pentoxifylline 400Mg Tablet in Pentoxifylline in 140 participants. Status unknown.
1 June 2017
Quick facts
| Lead sponsor | Taipei Medical University Hospital |
|---|---|
| Phase | Phase 2, PHASE3 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 140 |
| Start date | 1 May 2017 |
| Primary completion | 1 June 2017 |
| Estimated completion | 31 August 2017 |
Drugs / interventions tested
- Pentoxifylline 400Mg Tablet — full drug profile →
Conditions studied
- Pentoxifylline — all drugs for Pentoxifylline →
- Acute Kidney Injury — all drugs for Acute Kidney Injury →
Sponsor
Taipei Medical University Hospital
Who can join
Adults 20 to 70, any sex, with Pentoxifylline or Acute Kidney Injury. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Acute kidney injury (AKI) has a frequency of 7.0 % in hospital inpatients and is especially common in critically ill patients, in whom the prevalence of acute kidney injury is greater than 40% at admission to the intensive care unit if sepsis is present. Therefore, alternative strategies are required to confer better or more complete renoprotection for those who suffered from AKI. There had been many studies demonstrated that the phosphodiesterase inhibitor pentoxifylline (PTX) is a potent anti-inflammatory, anti-proliferative, and anti-fibrotic agent capable of attenuating experimental renal disease such as drugs, ischemic and sepsis induced AKI. We thereby design this controlled, non-randomized clinical trial, aiming at investigating the potential renoprotective efficacy of PTX, as compared to placebo, in 200 patients with AKI.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Molecular mechanisms and therapeutic interventions in acute kidney injury: a literature review.
He J, Chen Y, Li Y, Feng Y. · · 2025 · cited 5× · PMID 40121405 · DOI 10.1186/s12882-025-04077-4
Verify or expand the search:
- PubMed search for NCT02951299
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Taipei Medical University Hospital trials
Trials by the same sponsor.
- NCT07294469 — Menthol for Improving Movement and Sleep in Parkinson's Disease Patients · Phase 2 · not yet recruiting
- NCT07114289 — Spontaneous Breathing Trials Using Pressure Support or T-Piece in Overweight and Obese Patients · NA · recruiting
- NCT06949618 — Repetitive Transcranial Magnetic Stimulation in Cancer Pain Management · NA · not yet recruiting
- NCT05830578 — Clinical Validation of the Electrocardiogram Measurement · unknown
- NCT05877079 — TRPM8 in Acute Ischemic Stroke by Topical Menthol · Phase 2 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02951299 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Taipei Medical University Hospital
- Last refreshed: 26 April 2017
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02951299.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing